287 related articles for article (PubMed ID: 26069233)
1. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
Shimokawa H; Satoh K
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
[TBL] [Abstract][Full Text] [Related]
2. RhoA/Rho-Kinase in the Cardiovascular System.
Shimokawa H; Sunamura S; Satoh K
Circ Res; 2016 Jan; 118(2):352-66. PubMed ID: 26838319
[TBL] [Abstract][Full Text] [Related]
3. Rho-kinase: important new therapeutic target in cardiovascular diseases.
Satoh K; Fukumoto Y; Shimokawa H
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H287-96. PubMed ID: 21622831
[TBL] [Abstract][Full Text] [Related]
4. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
5. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.
Shi J; Wei L
J Cardiovasc Pharmacol; 2013 Oct; 62(4):341-54. PubMed ID: 23921309
[TBL] [Abstract][Full Text] [Related]
6. Light and Dark of Reactive Oxygen Species for Vascular Function: 2014 ASVB (Asian Society of Vascular Biology).
Shimokawa H; Satoh K
J Cardiovasc Pharmacol; 2015 May; 65(5):412-8. PubMed ID: 25162437
[TBL] [Abstract][Full Text] [Related]
7. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice.
Shimizu T; Fukumoto Y; Tanaka S; Satoh K; Ikeda S; Shimokawa H
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2780-91. PubMed ID: 24135024
[TBL] [Abstract][Full Text] [Related]
8. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.
Shimokawa H
J Cardiovasc Pharmacol; 2002 Mar; 39(3):319-27. PubMed ID: 11862109
[TBL] [Abstract][Full Text] [Related]
9. Rho kinase (ROCK) inhibitors.
Liao JK; Seto M; Noma K
J Cardiovasc Pharmacol; 2007 Jul; 50(1):17-24. PubMed ID: 17666911
[TBL] [Abstract][Full Text] [Related]
10. Rho kinase as a therapeutic target in cardiovascular disease.
Surma M; Wei L; Shi J
Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346
[TBL] [Abstract][Full Text] [Related]
11. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.
Barman SA; Zhu S; White RE
Vasc Health Risk Manag; 2009; 5():663-71. PubMed ID: 19707285
[TBL] [Abstract][Full Text] [Related]
12. Rho-kinase is an important therapeutic target in cardiovascular medicine.
Shimokawa H; Takeshita A
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1767-75. PubMed ID: 16002741
[TBL] [Abstract][Full Text] [Related]
13. Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling.
Zhang X; Zhang T; Gao F; Li Q; Shen C; Li Y; Li W; Zhang X
Mol Med Rep; 2015 Nov; 12(5):7317-25. PubMed ID: 26458725
[TBL] [Abstract][Full Text] [Related]
14. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
15. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.
Yu B; Sladojevic N; Blair JE; Liao JK
Expert Opin Ther Targets; 2020 Jan; 24(1):47-62. PubMed ID: 31906742
[No Abstract] [Full Text] [Related]
16. Progress of the study of rho-kinase and future perspective of the inhibitor.
Tawara S; Shimokawa H
Yakugaku Zasshi; 2007 Mar; 127(3):501-14. PubMed ID: 17329936
[TBL] [Abstract][Full Text] [Related]
17. Vascular rho kinases and their potential therapeutic applications.
Budzyn K; Sobey CG
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):590-6. PubMed ID: 17786858
[TBL] [Abstract][Full Text] [Related]
18. An Update on the Association of Protein Kinases with Cardiovascular Diseases.
Amin F; Ahmed A; Feroz A; Khaki PSS; Khan MS; Tabrez S; Zaidi SK; Abdulaal WH; Shamsi A; Khan W; Bano B
Curr Pharm Des; 2019; 25(2):174-183. PubMed ID: 30864507
[TBL] [Abstract][Full Text] [Related]
19. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological effects of RhoA and Rho-associated kinase on cardiovascular system.
Cai A; Li L; Zhou Y
J Hypertens; 2016 Jan; 34(1):3-10. PubMed ID: 26556565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
